Income Statement
EDGEWISE THERAPEUTICS, INC.
EWTX
Performance Overview
Click any row in the table to add it to this chart
in millions USD
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY | Dec 31, 2022 2022 FY | Dec 31, 2021 2021 FY |
|---|---|---|---|---|---|
|
Revenue
|
- | - | - | - | - |
|
Cost of Revenue
|
- | - | - | - | - |
|
Gross Profit
|
- | - | - | - | - |
|
Operating Expenses
|
191.41 | 158.83 | 114.36 | 71.66 | 43.22 |
|
Research & Development
|
151.39 | 126.97 | 90.91 | 54.03 | 32.19 |
|
Selling, General & Administrative
|
40.02 | 31.87 | 23.45 | 17.63 | 11.03 |
|
Other Operating Expenses
|
- | - | - | - | - |
|
Operating Income
|
-191.41 | -158.83 | -114.36 | -71.66 | -43.22 |
|
Non-Operating Income
|
- | - | - | - | - |
|
Interest Income
|
23.61 | 25.02 | 14.19 | 4.02 | 0.40 |
|
Interest Expense
|
- | - | - | - | - |
|
Other Non-Op Income / Expense
|
- | - | - | - | - |
|
Income Before Tax
|
-167.80 | - | - | - | - |
|
Income Tax Expense
|
- | - | - | - | - |
|
Non-Controlling Interest
|
- | - | - | - | - |
|
Net Income
|
-167.80 | -133.81 | -100.16 | -67.64 | -42.81 |
Supplemental
Per share data, derived & other items — not part of the income statement
in millions USD unless noted
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY | Dec 31, 2022 2022 FY | Dec 31, 2021 2021 FY |
|---|---|---|---|---|---|
|
Depreciation & Amortization
|
- | - | - | - | - |
|
EBITDA
|
-191.41 | -158.83 | -114.36 | -71.66 | -43.22 |
|
Earnings Per Share (Basic)
|
-1.63 | -1.45 | -1.57 | -1.26 | -1.14 |
|
Diluted EPS
|
-1.63 | -1.45 | -1.57 | -1.26 | -1.14 |
|
Weighted Average Shares
|
102.93 | 92.41 | 63.72 | 53.59 | 37.53 |
|
Diluted Weighted Avg Shares
|
102.93 | 92.41 | 63.72 | 53.59 | 37.53 |
|
Comprehensive Income
|
-167.54 | -133.49 | -98.71 | -68.48 | -43.33 |